Atara Biotherapeutics 미래 성장

Future 기준 확인 1/6

Atara Biotherapeutics은 연간 수입과 매출이 각각 47.9%와 17.8% 증가할 것으로 예상되고 EPS는 연간 27.2%만큼 증가할 것으로 예상됩니다.

주요 정보

47.9%

수익 성장률

27.2%

EPS 성장률

Biotechs 수익 성장	42.1%
매출 성장률	17.8%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	21 Aug 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:AT20 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	103	-67	-115	-60	4
12/31/2025	94	-98	-22	-39	6
12/31/2024	103	-91	-25	-6	6
6/30/2024	62	-181	-142	-142	N/A
3/31/2024	35	-233	-185	-184	N/A
12/31/2023	9	-276	-194	-193	N/A
9/30/2023	5	-290	-201	-199	N/A
6/30/2023	7	-305	-214	-213	N/A
3/31/2023	57	-215	-226	-224	N/A
12/31/2022	64	-228	-275	-270	N/A
9/30/2022	71	-247	-254	-248	N/A
6/30/2022	72	-248	-252	-242	N/A
3/31/2022	24	-350	-250	-239	N/A
12/31/2021	20	-340	-231	-221	N/A
9/30/2021	13	-328	-199	-190	N/A
6/30/2021	7	-318	-190	-184	N/A
3/31/2021	4	-311	-185	-179	N/A
12/31/2020	N/A	-307	-185	-181	N/A
9/30/2020	N/A	-304	-242	-235	N/A
6/30/2020	N/A	-301	-242	-235	N/A
3/31/2020	N/A	-298	-239	-232	N/A
12/31/2019	N/A	-291	-241	-236	N/A
9/30/2019	N/A	-292	-242	-234	N/A
6/30/2019	N/A	-279	-241	-230	N/A
3/31/2019	N/A	-256	-232	-215	N/A
12/31/2018	N/A	-231	-216	-180	N/A
9/30/2018	N/A	-186	-189	-147	N/A
6/30/2018	N/A	-159	-163	-119	N/A
3/31/2018	N/A	-135	N/A	-100	N/A
12/31/2017	N/A	-119	N/A	-88	N/A
9/30/2017	N/A	-102	N/A	-84	N/A
6/30/2017	N/A	-97	N/A	-79	N/A
3/31/2017	N/A	-88	N/A	-70	N/A
12/31/2016	N/A	-79	N/A	-60	N/A
9/30/2016	N/A	-82	N/A	-50	N/A
6/30/2016	N/A	-69	N/A	-48	N/A
3/31/2016	N/A	-65	N/A	-43	N/A
12/31/2015	N/A	-57	N/A	-37	N/A
9/30/2015	N/A	-46	N/A	-31	N/A
6/30/2015	N/A	-41	N/A	-22	N/A
3/31/2015	N/A	-30	N/A	-20	N/A
12/31/2014	N/A	-28	N/A	-17	N/A
9/30/2014	N/A	-21	N/A	-14	N/A
6/30/2014	N/A	-18	N/A	-12	N/A
3/31/2014	N/A	-15	N/A	-8	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AT20 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: AT20 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: AT20 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: AT20 의 수익(연간 17.8% ) German 시장( 5.7% 보다 빠르게 성장할 것으로 예상됩니다. 5.7% 연간).

고성장 수익: AT20 의 수익(연간 17.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AT20 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/09/14 03:28
장 마감 주가	2024/06/18 00:00
수익	2024/06/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Atara Biotherapeutics, Inc. 15 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
John Newman	Canaccord Genuity
Yigal Nochomovitz	Citigroup Inc
Jonathan Miller	Evercore ISI

Atara Biotherapeutics 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.72 loss in 1Q 2023)

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022)

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Independent Director recently bought €95k worth of stock

New minor risk - Market cap size

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022)

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Revenue and earnings growth

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

President recently sold €56k worth of stock

Atara Biotherapeutics, Inc. Announces Executive Changes

Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021)

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Third quarter 2022 earnings released: US$0.82 loss per share (vs US$0.91 loss in 3Q 2021)

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Atara Biotherapeutics, Inc. Announces Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

Atara and MSK Expects to Provide A Phase 1 Data Update for Ata2271 in Second Half 2022

Atara Biotherapeutics, Inc. Names Charlene Banard as Chief Technical Officer

Atara Biotherapeutics, Inc. Provides Update on ATA2271 Autologous CAR T Trial

Atara Biotherapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 28, 2022

FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million.

Atara Biotherapeutics, Inc. Lauds the Second High Impact Study This Month Solidifying EBV as the Primary Driver of the Development of MS

Atara Biotherapeutics, Inc. to Complete the Biologics License Application for Patients with EBV+ PTLD in Second Quarter of 2022

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

Atara Biotherapeutics, Inc. Announces New Preclinical and Preliminary Clinical Results for ATA2271 at ESMO Immuno-Oncology Congress 2021

Atara Biotherapeutics, Inc. Announces That the Marketing Authorization Application for Tabelecleucel (Tab-Cel®) Has Been Fully Validated by the European Medicines Agency

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of Tab-Cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ptld)

High number of new directors

Atara Biotherapeutics Announces Operational Progress on Tabelecleucel (Tab-Cel®) for Post-Transplant Lymphoproliferative Disease (PTLD)

SVP & Chief Commercial Officer recently bought €413k worth of stock

Atara Biotherapeutics Presents Positive Tab-Cel Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

Atara Biotherapeutics Presents New Long-Term Overall Survival Data from A Combined Analysis of Phase 2 Tab-Cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease At the Ebmt 2021 Annual Meeting

Atara Biotherapeutics, Inc. Reports Operational Progress

New 90-day low: €13.90

Atara Biotherapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

Atara Biotherapeutics Provides Regulatory Update for Tab-Cel(R) for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $174.999792 million.

Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219 at the 62 American Society of Hematology Annual Meeting

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

New 90-day high: €22.04

New 90-day high: €15.35

Atara Biotherapeutics, Inc. Presents New Preclinical Data on ATA3271 at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

Atara Biotherapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Atara Biotherapeutics, Inc. to Report Q2, 2020 Results on Aug 05, 2020

수익 및 매출 성장 예측